Summary of findings 3. Summary of findings table ‐ Starting long‐term oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage.
| Starting long‐term oral antiplatelet therapy compared to avoiding antithrombotic therapy for survivors of stroke due to intracerebral haemorrhage | ||||||
| Patient or population: survivors of stroke due to intracerebral haemorrhage Setting: Secondary care Intervention: starting long‐term oral antiplatelet therapy Comparison: avoiding antithrombotic therapy | ||||||
| Outcomes | Anticipated absolute effects* (95% CI) | Relative effect (95% CI) | № of participants (studies) | Certainty of the evidence (GRADE) | Comments | |
| Risk with avoiding antithrombotic therapy | Risk with starting long‐term oral antiplatelet therapy | |||||
| MACE assessed with: clinical assessment follow‐up: median 2 years | 228 per 1000 | 203 per 1000 (146 to 278) | RR 0.89 (0.64 to 1.22) | 536 (1 RCT) | ⊕⊕⊕⊝ Moderatea,b | |
| Death assessed with: clinical assessment follow‐up: median 2 years | 187 per 1000 | 201 per 1000 (142 to 285) | RR 1.08 (0.76 to 1.53) | 536 (1 RCT) | ⊕⊕⊕⊝ Moderatea,b | |
| All major occlusive vascular events assessed with: clinical assessment follow‐up: median 2 years | 142 per 1000 | 146 per 1000 (96 to 220) | RR 1.03 (0.68 to 1.55) | 536 (1 RCT) | ⊕⊕⊕⊝ Moderateb | |
| Intracerebral haemorrhage (ICH) assessed with: clinical assessment follow‐up: median 2 years | 86 per 1000 | 45 per 1000 (23 to 88) | RR 0.52 (0.27 to 1.03) | 536 (1 RCT) | ⊕⊕⊕⊝ Moderatea,b | |
| Fnctional status (mRS 0‐2) assessed with: clinical assessment follow‐up: 1 years | 433 per 1000 | 411 per 1000 (333 to 511) | RR 0.95 (0.77 to 1.18) | 461 (1 RCT) | ⊕⊕⊕⊝ Moderateb | |
| *The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: confidence interval; RR: risk ratio | ||||||
| GRADE Working Group grades of evidence High certainty: we are very confident that the true effect lies close to that of the estimate of the effect. Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different. Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect. Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect. | ||||||
| See interactive version of this table: https://gdt.gradepro.org/presentations/#/isof/isof_question_revman_web_431448890153987933. | ||||||
a The included randomised trial was open label but outcomes were objective. b Only one randomised trial with 537 participants.